The threshold of pentylenetetrazole-induced convulsive seizures, but not that of nonconvulsive seizures, is controlled by the nitric oxide levels in murine brains

Experimental Neurology

Volumn 247, Issue , 2013, Pages 645-652

  Watanabe, Masatomo ^a   Miyai, Asuka ^a   Danjo, Sonoko ^a,b   Nakamura, Yu ^b   Itoh, Kouichi ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Antiepileptic drugs; Electron paramagnetic resonance; Generalized seizure; Neuronal nitric oxide synthase; Nitric oxide; Pentylenetetrazole

Indexed keywords

ETHOSUXIMIDE; IONOTROPIC RECEPTOR ANTAGONIST; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PENTETRAZOLE; VALPROIC ACID;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; EX VIVO STUDY; GENE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; MOUSE; NERVE EXCITABILITY; NEURONAL NITRIC OXIDE SYNTHASE GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEIZURE; UPREGULATION;

(5S,10R)-(+)-5-METHYL-10,11-DIHYDRO-5H-DIBENZO[A,D]-CYCLOHEPTEN-5,10-IMINE MALEATE; (E)-(±)-2-AMINO-4-METHYL-5-PHOSPHO NO-3-PENTENOIC ACID ETHYL ESTER; 2,3-DIOXO-6-NITRO-1,2,3,4-TETRAHYDROBENZO[F]QUINOXALINE-7 -SULFONAMIDE; 3-(2-CHLOROPHENYL)-2-[2-[6-[(DIETHYLAMINO) METHYL]-2-PYRIDINYL]ETHENYL]-6-FLUORO-4(3H)-QUINAZOLINONE HYDROCHLORIDE; 3-BROMO-7-NITROINDAZOLE; 3BR7NI; AEDS; AMPA; AMPA RECEPTOR; AMPAR; ANTIEPILEPTIC DRUGS; CARBAMAZEPINE; CBZ; CGP39551; CP465022; DETC; DIMETHYL SULFOXIDE; DL-ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; DMSO; ELECTRON PARAMAGNETIC RESONANCE; EPR; ESM; ETHOSUXIMIDE; GABA(A)R; GAMMA-AMINOBUTYRIC ACID (A) RECEPTOR; GENERALIZED SEIZURE; L-NNA; LAMOTRIGINE; LTG; MK-801; NΩ-NITRO-L-ARGININE; N,N-DIETHYLDITHIOCARBAMATE NA; N-METHYL-D-ASPARTATE; NBQX; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NMDA; NMDA RECEPTOR; NMDAR; NNOS; NO; PENTYLENETETRAZOLE; PHENYTOIN; PHT; PTZ; S-METHYL L-THIOCITRULLINE; SMTC; SODIUM VALPROATE; VPA;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITROARGININE; PENTYLENETETRAZOLE; SEIZURES;

EID: 84881370137     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.02.019     Document Type: Article

References (26)

1. Banach M., Piskorska B., Czuczwar S.J., Borowicz K.K. Nitric oxide, epileptic seizures, and action of antiepileptic drugs. CNS Neurol. Disord. Drug Targets 2011, 10:808-819.
2. Chang B.S., Lowenstein D.H. Epilepsy. N. Engl. J. Med. 2003, 349:1257-1266.
3. Dorr A., Sled J.G., Kabani N. Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. NeuroImage 2007, 35:1409-1423.
4. Gotti S., Sica M., Viglietti-Panzica C., Panzica G. Distribution of nitric oxide synthase immunoreactivity in the mouse brain. Microsc. Res. Tech. 2005, 68:13-35.
5. Hara S., Kuriiwa F., Iwata N., Mukai T., Kano S., Endo T. Distinct effects of N omega-nitro-l-arginine on seizures induced by several drugs in mice. Pharmacol. Biochem. Behav. 1996, 53:673-677.
6. Hevel J.M., Marletta M.A. Nitric-oxide synthase assays. Methods Enzymol. 1994, 233:250-258.
7. Itoh K., Watanabe M. Paradoxical facilitation of pentylenetetrazole-induced convulsion susceptibility in mice lacking neuronal nitric oxide synthase. Neuroscience 2009, 159:735-743.
8. Itoh K., Watanabe M., Yoshikawa K., Kanaho Y., Berliner L.J., Fujii H. Magnetic resonance and biochemical studies during pentylenetetrazole-kindling development: the relationship between nitric oxide, neuronal nitric oxide synthase and seizures. Neuroscience 2004, 129:757-766.
9. Kaneko K., Itoh K., Berliner L.J., Miyasaka K., Fujii H. Consequences of nitric oxide generation in epileptic-seizure rodent models as studied by in vivo EPR. Magn. Reson. Med. 2002, 48:1051-1056.
10. Khosravani H., Zamponi G.W. Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol. Rev. 2006, 86:941-966.
11. Löscher W. In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats. Neurosci. Lett. 1993, 160:177-180.
12. Löscher W., Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-d-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 1991, 256:432-440.
13. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 1991, 8:171-189.
14. Löscher W., Rundfeldt C., Hönack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 1993, 5:1545-1550.
15. Mandhane S.N., Aavula K., Rajamannar T. Timed pentylenetetrazol infusion test: a comparative analysis with s.c. PTZ\ and MES models of anticonvulsant screening in mice. Seizure 2007, 16:636-644.
16. Menniti F.S., Buchan A.M., Chenard B.L., Critchett D.J., Ganong A.H., Guanowsky V., Seymour P.A., Welch W.M. CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 2003, 34:171-176.
17. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego. second edition.
18. Psarropoulou C., Matsokis N., Angelatou F., Kostopoulos G. Pentylenetetrazol-induced seizures decrease gamma-aminobutyric acid-mediated recurrent inhibition and enhance adenosine-mediated depression. Epilepsia 1994, 35:12-19.
19. Rocha L., Ackermann R.F., Engel J. Chronic and single administration of pentylenetetrazol modifies benzodiazepine receptor-binding: an autoradiographic study. Epilepsy Res. 1996, 24:65-72.
20. Rogawski M.A., Löscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 2004, 5:553-564.
21. Shorvon S.D. Drug treatment of epilepsy in the century of the ILAE: the first 50years, 1909-1958. Epilepsia 2009, 50(Suppl. 3):69-92.
22. Snyder S.H., Bredt D.S. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 1991, 12:125-128.
23. Societas Neurologica Japonica Guideline for Epilepsy Diagnose and Treatment in Japan 2010, Igaku-Shoin Ltd., Tokyo.
24. Somerville E.R. Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia 2009, 50:31-36.
25. Watanabe Y., Takechi K., Fujiwara A., Kamei C. Effects of antiepileptics on behavioral and electroencephalographic seizure induced by pentetrazol in mice. J. Pharmacol. Sci. 2010, 112:282-289.
26. World Health Organization (WHO) Epilepsy Fact sheet N°999 http://www.who.int/mediacentre/factsheets/fs999/en/index.html.